Evidence map›Paper›PMID 42094387›Full record

ArticlebioRxiv : the preprint server for biology2026

Bloom syndrome helicase is required for efficient HIV-1 reverse transcription in macrophages.

Andrew A Leal, Samantha Tafrate, Xianbao He, Daniel L Bryant, Melissa B Herring, Maria Andrade, Joseph B McWhirter, Andrés A Quiñones-Molina, Suryaram Gummuluru, Manish Sagar and 3 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Andrew A LealDepartment of Virology, Immunology & Microbiology, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.ORCID 0000-0003-3020-9131
Samantha TafrateDepartment of Medicine, Section of Infectious Diseases, Boston Medical Center, Boston, Massachusetts, USA.
Xianbao HeDepartment of Medicine, Section of Infectious Diseases, Boston Medical Center, Boston, Massachusetts, USA.ORCID 0000-0003-2448-8437
Daniel L BryantDepartment of Medicine, Section of Infectious Diseases, Boston Medical Center, Boston, Massachusetts, USA.
Melissa B HerringDepartment of Medicine, Section of Infectious Diseases, Boston Medical Center, Boston, Massachusetts, USA.ORCID 0009-0004-8834-3936
Maria AndradeDepartment of Medicine, Section of Infectious Diseases, Boston Medical Center, Boston, Massachusetts, USA.
Joseph B McWhirterDepartment of Virology, Immunology & Microbiology, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.ORCID 0000-0002-0186-8472
Andrés A Quiñones-MolinaDepartment of Virology, Immunology & Microbiology, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.
Suryaram GummuluruDepartment of Virology, Immunology & Microbiology, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.ORCID 0000-0002-8606-8481
Manish SagarDepartment of Virology, Immunology & Microbiology, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.ORCID 0000-0001-9803-6594
Rachel L FlynnDepartment of Pharmacology, Physiology & Biophysics, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.
Ignaty LeshchinerDepartment of Computational Biomedicine, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.
Andrew J HendersonDepartment of Virology, Immunology & Microbiology, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.ORCID 0000-0002-9299-5302

Funding

Translational ScienceP30AI042853 · NIAID · MIRIAM HOSPITAL · PI CURT G BECKWITH, DEBBIE M. CHENG · 1998 to 2026
$51.7M
RESEARCH TRAINING IN IMMUNOLOGYT32AI007309 · NIAID · BOSTON UNIVERSITY MEDICAL CAMPUS · PI GUMMULURU, SURYARAM · 1988 to 2024
$7.4M
Persistent HIV-1 expression and microglia dysfunctionR01DA055488 · NIDA · BOSTON MEDICAL CENTER · PI GUMMULURU, SURYARAM, HENDERSON, ANDREW J · 2021 to 2025
$3.7M
Defective HIV proviruses and Persistent Innate Immune ActivationR01AI187175 · NIAID · BOSTON MEDICAL CENTER · PI SURYARAM GUMMULURU, Andrew J Henderson · 2024 to 2026
$2.4M
Mechanisms of Persistent Inflammasome Activation in Myeloid CellsR01DA059952 · NIDA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI SURYARAM GUMMULURU, Andrew J Henderson · 2024 to 2026
$2.3M
NIAID NIH HHS P30 AI042853NIAID NIH HHS R01 AI187175NIAID NIH HHS T32 AI007309NIDA NIH HHS R01 DA055488NIDA NIH HHS R01 DA059952
6 · The paper itself

Abstract

The induction of DNA damage by HIV-1 prior to integration suggests a function for DNA damage responses (DDR) during early infection, however what this role is remains incompletely understood. Initial experiments, using specific inhibitors for DDR pathways demonstrate that both ATM and ATR are necessary for efficient HIV-1 infection of macrophages with ATM acting at the late reverse transcription step. To identify DDR factors associated with ATM/ATR pathways that influence HIV-1 infection, a CRISPR knockout screen using a DDR-focused sgRNA library was performed. Approximately 30 DDR genes that impacted HIV-1 infection were identified with 13 factors that facilitated HIV-1 infection and 17 DDR factors that restrict HIV-1 infection. Several hits were factors associated with the Fanconi anemia pathway, such as BTR complex proteins, including the RecQ helicase Bloom syndrome helicase. BLM was specifically demonstrated to enhance HIV-1 infection and replication with knockdown of BLM expression diminishing integration and the establishment of intact HIV-1 proviruses in macrophages by 50%. BLM is associated with HIV-1 late reverse transcription intermediates, the step that proceeds HIV-1 integration. These findings identify BLM as a DDR host factor that promotes early HIV-1 infection by facilitating completion of reverse transcription and subsequent integration.

Indexed as

BLMDNA damageHIVHost-pathogen interactionMacrophage infection

Identifiers

PMID42094387
PMCPMC13142392

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.